OKYO Pharma Limited (OKYO)
| Bid | 1.8 |
| Market Cap | 64.38M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.09K |
| EPS (ttm) | -0.38 |
| PE Ratio (ttm) | -5 |
| Forward PE | -14.46 |
| Analyst | Buy |
| Ask | 1.97 |
| Volume | 42,590 |
| Avg. Volume (20D) | 127,376 |
| Open | 1.81 |
| Previous Close | 1.86 |
| Day's Range | 1.81 - 1.90 |
| 52-Week Range | 0.81 - 1.98 |
| Beta | -4.30 |
About OKYO
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for OKYO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
3 weeks ago · proactiveinvestors.com
OKYO Pharma CEO to present drug research for debilitating eye pain at Boston summitOKYO Pharma Ltd (NASDAQ:OKYO) shares could see renewed attention this week as the company's chief executive, Gary Jacob, is set to present findings on its lead drug candidate at a biotech conference i...
1 month ago · proactiveinvestors.com
OKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal painOKYO Pharma Ltd (NASDAQ:OKYO) announced that the US Food and Drug Administration has granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain (NCP), a chronic ocular c...
1 month ago · proactiveinvestors.com
OKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal painOKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to accelerate the clinical development of urcosimod, formerly called OK-101, to treat neuropathic corneal pain. The company has chosen to end its Phas...
2 months ago · proactiveinvestors.com
OKYO Pharma CEO discusses FDA Fast Track filing for urcosimod - ICYMIOKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the company's recent developments, including the formal naming of its drug candidate OK-101 as urcosimod. Jacob discussed the c...
2 months ago · proactiveinvestors.com
OKYO Pharma reports long-term shelf stability of corneal pain treatmentOKYO Pharma Ltd (NASDAQ:OKYO) said on Monday that its experimental drug urcosimod has demonstrated stability for over two and a half years in single-use ampoules. The biopharmaceutical company's confi...
3 months ago · proactiveinvestors.com
OKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatmentOKYO Pharma Ltd (NASDAQ:OKYO) announced that it has filed a Fast Track designation application with the US Food and Drug Administration (FDA) for urcosimod, for the treatment of neuropathic corneal pa...